Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$9.26 - $14.36 $2.4 Million - $3.71 Million
-258,700 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$9.84 - $14.26 $1.42 Million - $2.06 Million
-144,700 Reduced 35.87%
258,700 $2.8 Million
Q3 2020

Nov 16, 2020

BUY
$10.3 - $21.64 $460,410 - $967,308
44,700 Added 12.46%
403,400 $4.16 Million
Q2 2020

Aug 14, 2020

BUY
$8.53 - $25.64 $1.15 Million - $3.44 Million
134,300 Added 59.85%
358,700 $7.49 Million
Q1 2020

May 15, 2020

SELL
$7.98 - $16.32 $1.33 Million - $2.72 Million
-166,500 Reduced 42.59%
224,400 $10.2 Million
Q4 2019

Jan 31, 2020

BUY
$5.12 - $12.22 $2 Million - $4.78 Million
390,900 New
390,900 $4.5 Million

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.